Related references
Note: Only part of the references are listed.Preliminary Assessment of the Efficacy of a T-Cell-Based Influenza Vaccine, MVA-NP+M1, in Humans
Patrick J. Lillie et al.
CLINICAL INFECTIOUS DISEASES (2012)
Potent CD8(+) T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1
Tamara K. Berthoud et al.
CLINICAL INFECTIOUS DISEASES (2011)
Contributions of Antinucleoprotein IgG to Heterosubtypic Immunity against Influenza Virus
Mark W. LaMere et al.
JOURNAL OF IMMUNOLOGY (2011)
Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus Clearance
Mark W. LaMere et al.
JOURNAL OF VIROLOGY (2011)
Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein
Lina Guo et al.
ARCHIVES OF VIROLOGY (2010)
CURRENT CONCEPTS Influenza Vaccines for the Future
Linda C. Lambert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
An Influenza A/H1N1/2009 Hemagglutinin Vaccine Produced in Escherichia coli
Jose M. Aguilar-Yanes et al.
PLOS ONE (2010)
Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines
Kanyarat Thueng-in et al.
VACCINE (2010)
Moving influenza vaccines forward
Suryaprakash Sambhara et al.
EXPERT REVIEW OF VACCINES (2009)
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara
Guus F. Rimmelzwaan et al.
EXPERT REVIEW OF VACCINES (2009)
Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus
Zuzana Biesova et al.
VACCINE (2009)
Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses
Graeme E. Price et al.
VACCINE (2009)
Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza a virus
J. H. C. M. Kreijtz et al.
JOURNAL OF VIROLOGY (2008)
Efficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs
Langzhou Song et al.
PLOS ONE (2008)
Cross-subtype immunity against avian influenza in-persons recently vaccinated for influenza
Cristiana Gioia et al.
EMERGING INFECTIOUS DISEASES (2008)
Evolutionarily Conserved Protein Sequences of Influenza A Viruses, Avian and Human, as Vaccine Targets
A. T. Heiny et al.
PLOS ONE (2007)
Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity
Kenji Ohba et al.
VACCINE (2007)
Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1
Oleg P. Zhirnov et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2007)
Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice
J. H. C. M. Kreijtz et al.
VACCINE (2007)
Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005
Alan W. Hampson et al.
VACCINE (2006)
Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses
AD Altstein et al.
ARCHIVES OF VIROLOGY (2006)
Making better influenza virus vaccines?
P Palese
EMERGING INFECTIOUS DISEASES (2006)
Share Paper
